...
首页> 外文期刊>Genetics and molecular biology: publication of the Sociedade Brasileira de Genetica >Assessment of the toxicogenic effects and cell death potential of the ester (Z)-methyl 4-((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)-4-oxobut-2-anoate in combination with cisplatin, cyclophosphamide and doxorubicin
【24h】

Assessment of the toxicogenic effects and cell death potential of the ester (Z)-methyl 4-((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)-4-oxobut-2-anoate in combination with cisplatin, cyclophosphamide and doxorubicin

机译:酯(Z)-甲基4-((1,5-二甲基-3-氧代-2-苯基-2,3-二氢-1H-吡唑-4-基)氨基)-4-氧代丁-2-酸根与顺铂,环磷酰胺和阿霉素的组合

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Despite rapid advances in both the early detection and treatment of cancer, the mortality from this disease remains high, which justifies the development of new products that are more selective and effective and have fewer side effects. Accordingly, a novel ester was synthesized that contains two pharmacophores with important biological activities: (I) 4-aminoantipyrine, which has anti-inflammatory and antioxidant effects, and (II) the pharmacophore 1,4-dioxo-butenyl, which has cytotoxic activity. When administered alone, this compound is non-genotoxic, and it does not cause an increasing in splenic phagocytosis. Nevertheless, it can induce cell death. When administered in combination with commercial chemotherapeutic agents, such as doxorubicin, cisplatin, and cyclophosphamide, the ester shows antigenotoxic activity and decreases phagocytosis and reduces the potential to cause cell death. These results indicate that the compound should not be used in combination with chemotherapeutic agents that exert their effect through DNA damage, an important feature of antitumor drugs.
机译:尽管在癌症的早期发现和治疗方面都取得了飞速的进步,但该疾病的死亡率仍然很高,这证明了开发更具选择性和有效性且副作用较小的新产品的合理性。因此,合成了一种新型酯,其包含具有重要生物学活性的两个药效基团:(I)具有消炎和抗氧化作用的4-氨基安替比林,以及(II)具有细胞毒活性的药效基团1,4-二氧代丁烯基。当单独给药时,该化合物是非遗传毒性的,并且不会引起脾吞噬作用的增加。然而,它可以诱导细胞死亡。与商业化学治疗剂(如阿霉素,顺铂和环磷酰胺)联合给药时,该酯显示出抗原毒性活性并减少吞噬作用,并降低了引起细胞死亡的可能性。这些结果表明该化合物不应与通过DNA损伤发挥作用的化学治疗剂组合使用,而DNA损伤是抗肿瘤药物的重要特征。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号